

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 July 2024 (11.07.2024)



(10) International Publication Number
WO 2024/148040 A1

(51) International Patent Classification:
A61P 25/06 (2006.01) *C07D 487/10* (2006.01)

(21) International Application Number:
PCT/US2024/010110

(22) International Filing Date:
03 January 2024 (03.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/478,409 04 January 2023 (04.01.2023) US

(71) Applicants: **4E THERAPEUTICS, INC.** [US/US]; 3800 N. Lamar Blvd. Suite 200, Austin, Texas 78756 (US). **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, Texas 78701 (US).

(72) Inventors: **PRICE, Theodore J.**; c/o 4E Therapeutics, Inc., 3800 N. Lamar Blvd. Suite 200, Austin, Texas 78756 (US). **SAHN, James J.**; c/o 4E Therapeutics, Inc., 3800 N. Lamar Blvd. Suite 200, Austin, Texas 78756 (US). **RIXSON, Daniel**; c/o Macfarlan Smith Limited, Wheatfield Road, Edinburgh EH11 2QA, Scotland (GB). **SULEIMAN, Osama**; c/o Macfarlan Smith Limited, Wheatfield Road, Edinburgh EH11 2QA, Scotland (GB). **CASTELHANO, Arlindo Lucas**; c/o Davos Chemical Corporation, 600 East Crescent Ave., Upper Saddle River, New Jersey 07458 (US). **SMITH, Garry Robert**; c/o Davos Chemical Corporation, 600 East Crescent Ave., Upper Saddle River, New Jersey 07458 (US).

(74) Agent: **D'AMATO, Erica M.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,


NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SOLID STATE FORMS OF MNK INHIBITORS



(57) Abstract: The present disclosure relates to solid forms of a compound having the following Structure (I): or a tautomer thereof. The present disclosure is also directed to methods of making and using a compound of Structure (I).

WO 2024/148040 A1